FOLFOX
Showing 1 - 25 of 888
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)
Not yet recruiting
- Metastatic Colorectal Cancer
- +2 more
- Onvansertib
- +3 more
- (no location specified)
Oct 24, 2023
Locally Advanced Colorectal Carcinoma Trial in Beijing (Cadonilimab, FOLFOX regimen)
Recruiting
- Locally Advanced Colorectal Carcinoma
- Cadonilimab
- FOLFOX regimen
-
Beijing, Beijing, ChinaCancer Hospital/ National Cancer Center, Chinese Academy of Medi
Nov 23, 2023
Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)
Recruiting
- Colorectal Cancer
- Peritoneal Metastases
- Irinotecan
- +2 more
-
Eindhoven, Netherlands
- +1 more
Aug 15, 2023
Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- toripalimab FOLFOX
- (no location specified)
Aug 3, 2023
Unresectable or Metastatic Colorectal Cancer Trial in Shenyang (FOLFOX/FOLFIRI)
Recruiting
- Unresectable or Metastatic Colorectal Cancer
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital & Institute
Mar 22, 2023
Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)
Not yet recruiting
- Potentially Resectable Hepatocellular Carcinoma
- (no location specified)
Nov 16, 2023
Intrahepatic Cholangiocarcinoma Trial in Tianjin (Regorafenib and HAIC, FOLFOX)
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- Regorafenib and HAIC
- FOLFOX
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Sep 7, 2022
Hepatocellular Carcinoma Trial in Foshan, Guangzhou (HAIC, FOLFOX 2d, FOLFOX 1d)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Foshan, Guangdong, China
- +2 more
Jul 26, 2022
Cancer, Gastro-Intestinal Intraepithelial Neoplasia Trial in Jerusalem (Promitil)
Active, not recruiting
- Cancer
- Gastro-Intestinal Intraepithelial Neoplasia
-
Jerusalem, IsraelShaare Zedek Medical Center
Dec 21, 2022
Colorectal Cancer Trial (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV,
Not yet recruiting
- Colorectal Cancer
- HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
- HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- (no location specified)
Jul 13, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)
Recruiting
- Hepatocellular Carcinoma
- Atezolizumab
- +2 more
-
Guangzhou, Guangdong, ChinaCancer Center Sun Yat-sen University
May 24, 2023
New Prognostic Score for Adult RAS Wild-type mCRC Treated With
Active, not recruiting
- Metastatic Colorectal Cancer
- RAS Wild-type
-
Freiburg, Baden-Württemberg, GermanyPraxis für interdisziplinäre Onkologie & Hämatologie
Jul 29, 2022
Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)
Recruiting
- Colorectal Cancer Metastatic
- Dexamethasone
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Feb 3, 2023
Gastric Cancer, Peritoneal Carcinomatosis Trial in Vilnius (Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal
Recruiting
- Gastric Cancer
- Peritoneal Carcinomatosis
- Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy
-
Vilnius, Vilniaus, Lithuania
- +1 more
Jan 3, 2023
Colorectal Cancer Trial in Madrid (FOLFOX regimen, Panitumumab, Bevacizumab)
Recruiting
- Colorectal Cancer
- FOLFOX regimen
- +3 more
-
Madrid, SpainSpanish Cooperative Group for the Treatment of Digestive Tumors
Mar 8, 2022
Advanced Rectal Cancer Trial in Rochester (FOLFOX)
Active, not recruiting
- Advanced Rectal Cancer
- FOLFOX
-
Rochester, New York
- +1 more
Jun 9, 2022
Cholangiocarcinoma, Intrahepatic Trial in Beijing (Recombinant Human Adenovirus Type 5, HAIC of FOLFOX)
Not yet recruiting
- Cholangiocarcinoma, Intrahepatic
- Recombinant Human Adenovirus Type 5
- HAIC of FOLFOX
-
Beijing, Beijing, ChinaBeijing Tsinghua Chang Gung Hospital
Mar 16, 2022
Colorectal Cancer Trial in Guangzhou (FOLFOX , FOLFIRI or FOLFOXIRI regimens, FOLFOX regimen)
Not yet recruiting
- Colorectal Cancer
- FOLFOX , FOLFIRI or FOLFOXIRI regimens
- FOLFOX regimen
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
Apr 26, 2023
Esophagogastric Cancer, HER2-Negative Trial in United States (regorafenib, nivolumab, FOLFOX chemo with oxaliplatin)
Active, not recruiting
- Esophagogastric Cancer
- HER2-Negative
- regorafenib
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Nov 23, 2022
Metastatic Colorectal Cancer Trial in Shanghai (Fruquintinib, FOLFIRI, mFOLFOX6)
Not yet recruiting
- Metastatic Colorectal Cancer
- Fruquintinib
- +2 more
-
Shanghai, Shanghai, ChinaDepartment of Colorectal Surgery Fudan University Shanghai Caner
Nov 23, 2022
Hepatocellular Carcinoma Trial in Guangzhou (Raltitrexed, oxaliplatin (SALOX) treatment, Oxaliplatin, fluorouracil/leucovorin
Recruiting
- Hepatocellular Carcinoma
- Raltitrexed, oxaliplatin (SALOX) treatment
- Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
-
Guangzhou, Guangdong, ChinaDepartment of Minimally Invasive and Interventional Radiology, L
May 17, 2022
Post-orthotopic Liver Transplantation, Hepatocellular Carcinoma Recurrent Trial in Nanjing (Bevacizumab Biosimilar IBI305)
Not yet recruiting
- Post-orthotopic Liver Transplantation
- Hepatocellular Carcinoma Recurrent
- Bevacizumab Biosimilar IBI305
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital
May 5, 2022
Gastric Cancer Trial in ZhengZhou (SHR1210 combined with FOLFOX)
Active, not recruiting
- Gastric Cancer
- SHR1210 combined with FOLFOX
-
ZhengZhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jan 11, 2022